Cardiology Plus

​Jun Ren, MD, PhD, FAHA.

Associate Editor-in-Chief, Cardiology Plus

Zhongshan Hospital Fudan University, Shanghai, China;

Department of Laboratory Medicine and Pathology, University of Washington, Washington, USA

Dr. Jun Ren is a professor of cardiology and pharmacology at Zhongshan Hospital Fudan University in Shanghai, China after a long-tenure in US institutes. His area of research is focused on cardiac pathophysiology in alcoholism, diabetes mellitus, obesity and aging, and development of targeted drug therapy for these comorbidities. He serves on the board of many scientific journals and academic research programs in China and worldwide. He is a Clarivate Highly cited scholar with a H-index of 103.

Yinzi Jin, Ph.D.

Guest Editor of Cardiology Plus

School of Public Health,

Peking University, Beijing, China

Dr. Yinzi Jin is an assistant professor at the School of Public Health at Peking University, Beijing, China. Her research focuses on designing and implementing evidence-based interventions to improve the quality of care for patients with cardiovascular diseases in low and middle-income countries. She has studied a wide range of innovations including quality improvement in clinical pathway, clinical information systems, and integrated healthcare delivery models. She served as Health Systems Global, Emerging Voices Governance Board Member for the Western Pacific region, and Advisory Board Member of the BMJ Quality & Safety.

Asli F. Ceylan, Ph.D.

Guest Editor of Cardiology Plus

Department of Pharmaceutical Sciences, Ankara Yildirim Beyazit University, Ankara, Turkey

Dr. Asli F. Ceylan is a professor of pharmaceutical sciences at Ankara Yildirim Beyazit University, Ankara, Turkey. Her area of research is focused on cardiac pathophysiology in diabetes, obesity and aging, and development of targeted drug therapy in these conditions. She serves on editorial board of several international journals.

Main Purpose of the Special Issue:

Comprehensively evaluate the genetic and epigenetic changes in cardiovascular diseases and exploration of potential therapeutic target for drug therapy, and healthcare management practice.

Outline

Topics include, but are not limited to, the following:

1. Comprehensive expert review of the genetic and epigenetic changes in cardiovascular diseases;
2. Estimating the contribution of different public health risk factors on the management of cardiovascular diseases;

We also welcome novel and innovative approaches for public health issues and "omics" for a broad range of possible therapeutic targets for cardiovascular disease. Emerging topics in this field of cardiovascular diseases such as impact of COVID-19 and epidemiology are also welcome.

Words limit:

For other article types, please refer to author’s instructions: https://journals.lww.com/ cardioplus/ Pages/instructionsforauthors.aspx#17.

Accepted papers will be published continuously in the Cardiology Plus (as soon as accepted) and will be listed together on the Special Issue website

Cardiology Plus Submission System:

https://www.editorialmanager.com/cardioplus/default1.aspx 

Please indicate in the cover letter that your article is for “Genetic and epigenetic therapy of cardiovascular Diseases”. The submission deadline is May 31, 2023.We are looking forward to your articles!

About the Cardiology Plus